Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)
NCT: NCT04358926 · COMPLETED
Brief Summary
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic.So far, no specific treatment has proven efficacy. Recent case series reported the use of Hyperbaric Oxygen Therapy (HBOT) on 5 severe COVID-19 patients who developed respiratory insufficiency. HBOT mechanisms of tissue oxygenation and anti-inflammatory effect may explain these findings. The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner.
Frequently Asked Questions
What is Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)?
Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19) is a clinical trial registered under NCT04358926. Current status: COMPLETED.
What is the status of NCT04358926?
The current status of NCT04358926 (Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)) is: COMPLETED.
When did Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19) start?
Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19) started on 2020-04-30.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.